Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling

Vascular Pharmacology

Volumn 41, Issue 4-5, 2004, Pages 167-176

  Hafizi, Sassan ^a,b   Mordi, Vanessa N ^a   Andersson, Klara M ^a   Chester, Adrian H ^a   Yacoub, Magdi H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Coronary; Human; Immunosuppressants; Proliferation; Vascular smooth muscle cells

Indexed keywords

CYCLOSPORIN A; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; S6 KINASE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CYTOKINE RELEASE; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

AUTOCRINE COMMUNICATION; BINDING, COMPETITIVE; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; CYCLOSPORINE; GROWTH INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 10644288652     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2004.10.002     Document Type: Article

References (39)

1. H.Ø. Andersen Heart allograft vascular disease. An obliterative vascular disease in transplanted hearts Atherosclerosis 142 1999 243 263
2. C. Atkinson, J. Horsley, S. Rhind-Tutt, S. Charman, C.J. Phillpotts, J. Wallwork, and M.J. Goddard Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin J. Heart Lung Transplant. 23 2004 427 435
3. J.M. Bellon, J. Bujan, F. Jurado, A. Hernando, N.G. Honduvilla, and B. Dominguez Cyclosporin A delays the presentation of intimal hyperplasia in an experimental model of arterial autograft Eur. Surg. Res. 28 1996 39 48
4. F. Braun, T. Lorf, and B. Ringe Update of current immunosuppressive drugs in clinical organ transplantation Transpl. Int. 11 1998 77 81
5. E.J. Brown, P.A. Beal, C.T. Keith, J. Chen, T.B. Shin, and S.L. Schreiber Control of p70 s6 kinase by kinase activity of FRAP in vivo Nature 377 1995 441 446
6. W. Cao, P. Mohacsi, R. Shorthouse, R. Pratt, and R.E. Morris Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506 Transplantation 59 1995 390 395
7. J.F. DiJoseph, E. Fluhler, J. Armstrong, M. Sharr, and S.N. Sehgal Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat Transplantation 62 1996 1109 1112
8. G. Ferns, M. Reidy, and R. Ross Vascular effects of cyclosporine A in vivo and in vitro Am. J. Pathol. 137 1990 403 413
9. M. Goppelt-Struebe, B. Esslinger, and U. Kunzendorf Failure of cyclosporin A to induce transforming growth factor b (TGF-b) synthesis in activated peripheral blood lymphocytes Clin. Transplant. 17 2003 20 25
10. C.R. Gregory, P. Huie, M.E. Billingham, and R.E. Morris Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury Transplantation 55 1993 1409 1418
11. S. Hafizi, A.H. Chester, S.P. Allen, K. Morgan, and M.H. Yacoub Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade Coron. Artery Dis. 9 1998 167 175
12. S. Hafizi, R. Nobin, S.P. Allen, A.H. Chester, and M.H. Yacoub Contrasting effects of platelet-derived growth factor (PDGF) isomers on mitogenesis, contraction and intracellular calcium concentration in human vascular smooth muscle Acta Physiol. Scand. 164 1998 191 199
13. A receptor and is co-mitogenic with growth factors Atherosclerosis 146 1999 351 359
14. S. Hafizi, X. Wang, A.H. Chester, M.H. Yacoub, and C.G. Proud ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells Am. J. Physiol., Heart Circ. Physiol. 287 2004 H1232 H1238
15. L. Jonasson, J. Holm, and G.K. Hansson Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury Proc. Natl. Acad. Sci. U. S. A. 85 1988 2303 2306
16. A.K. Khanna, V.R. Cairns, C.G. Becker, and J.D. Hosenpud Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine Transplantation 67 1999 882 889
17. J. Kunz, and M.N. Hall Cyclosporin A, FK506 and rapamycin: more than just immunosuppression Trends Biochem. Sci. 18 1993 334 338
18. D. Leszczynski, Y. Zhao, T.J. Yeagley, and M.L. Foegh Direct and endothelial cell-mediated effect of cyclosporin A on the proliferation of rat smooth muscle cells in vitro Am. J. Pathol. 142 1993 149 155
19. S.O. Marx, T. Jayaraman, L.O. Go, and A.R. Marks Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells Circ. Res. 76 1995 412 417
20. A.D. Mayer, J. Dmitrewski, J.P. Squifflet, T. Besse, B. Grabensee, B. Klein, F.W. Eigler, U. Heemann, R. Pichlmayr, M. Behrend, Y. Vanrenterghem, J. Donck, J. van Hooff, M. Christiaans, J.M. Morales, A. Andres, R.W. Johnson, C. Short, B. Buchholz, N. Rehmert, W. Land, S. Schleibner, J.L. Forsythe, D. Talbot, and E. Pohanka Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group Transplantation 64 1997 436 443
21. B.M. Meiser, M.E. Billingham, and R.E. Morris Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease Lancet 338 1991 1297 1298
22. cdc2 kinase activation in T lymphocytes J. Biol. Chem. 268 1993 22737 22745
23. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, R.P. Caputo, D.J. Kereiakes, D.O. Williams, P.S. Teirstein, J.L. Jaeger, and R.E. Kuntz Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N. Engl. J. Med. 349 2003 1315 1323
24. J. Nilsson Cytokines and smooth muscle cells in atherosclerosis Cardiovasc. Res. 27 1993 1184 1190
25. M. Poon, S.O. Marx, R. Gallo, J.J. Badimon, M.B. Taubman, and A.R. Marks Rapamycin inhibits vascular smooth muscle cell migration J. Clin. Invest. 98 1996 2277 2283
26. D.J. Price, J.R. Grove, V. Calvo, J. Avruch, and B.E. Bierer Rapamycin inhibition of the 70-kilodalton S6 protein kinase Science 257 1992 973 977
27. C.G. Proud p70 S6 kinase: an enigma with variations Trends Biochem. Sci. 21 1996 181 185
28. S. Sawada, G. Suzuki, Y. Kawase, and F. Takaku Novel immunosuppressive agent, FK506: in vitro effects on the cloned T cell activation J. Immunol. 139 1987 1797
29. C. Schmid, U. Heemann, H. Azuma, and N.L. Tilney Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts Transplantation 60 1995 729 733
30. J. Schofer, M. Schluter, A.H. Gershlick, W. Wijns, E. Garcia, E. Schampaert, and G. Breithardt Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) Lancet 362 2003 1093 1099
31. S.N. Sehgal, J.S. Camardo, J.A. Scarola, and B.T. Maida Rapamycin (sirolimus, rapamune) Curr. Opin. Nephrol. Hypertens. 4 1995 482 487
32. 1 in humans Transplantation 65 1998 313 318
33. S.H. Snyder, and D.M. Sabatini Immunophilins and the nervous system Nat. Med. 1 1995 32 37
34. R.L. Stoltenberg, J. Geraghty, D.M. Steele, E. Kennedy, D.A. Hullett, and H.W. Sollinger Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine Transplantation 60 1995 993 998
35. J. Thyberg, and G.K. Hansson Cyclosporine A inhibits induction of DNA synthesis by PDGF and other peptide mitogens in cultured rat aortic smooth muscle cells and dermal fibroblasts Growth Factors 4 1991 209 219
36. S.R. von Manteuffel, A.C. Gingras, X.F. Ming, N. Sonenberg, and G. Thomas 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase Proc. Natl. Acad. Sci. U. S. A. 93 1996 4076 4080
37. M.D. Vu, S. Qi, D. Xu, J. Wu, W.E. Fitzsimmons, S.N. Sehgal, L. Dumont, S. Busque, P. Daloze, and H. Chen Tacrolimus (FK506) and Sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat Transplantation 64 1997 1853 1856
38. J.R. Waller, G.J. Murphy, G.R. Bicknell, D. Toomey, and M.L. Nicholson Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia Br. J. Surg. 89 2002 1390 1395
39. C.J.E. Watson, P.J. Friend, N.V. Jamieson, T.W. Frick, G. Alexander, A.E. Gimson, and R. Calne Sirolimus: a potent new immunosuppressant for liver transplantation Transplantation 67 1999 505 509